Remifentanil was designed to serve as a strong anesthetic with an ultra-short and predictable duration that would not have accumulation issues. Remifentanil is patented by Glaxo Wellcome Inc. and was FDA approved on July 12, 1996. Pricing for Ultiva. 1 mg vial - 30.19 USD; 3 mg vial - 57.20 USD; 5 mg vial - 118.15 USD
Breach of contract is a legal cause of action in which a binding agreement or bargained-for exchange is not honored by one or more of the parties to the contract by non-performance or interference with the other party's performance.
If a party, who agreed to formulate a contract with another party, does not fulfill his or her contractual promise or has given information to the other party that he or she will not perform his expected duty as labeled in the contract, the party is said to have performed a breach of contract.